Skip to main content
Deutsch

Search

  1. Home
  2. Search

Webseiten-Inhalte

MMAM 2018 - Moscow Mollecular Allergology Meeting | MedUni Vienna ...All Events We are very glad to announce the 1st Moscow Molecular Allergology Meeting (MMAM 2018) organized by NRC Institute of Immunology FMBA of Russia, Russian Association of Allergology and Clinical Immunology (RAAСI), Medical University of Vienna and International Network of Universities for Molecular Allergology and Immunology (INUNIMAI). The main focus of the MMAM 2018 is the development of new strategies for diagnosis and therapy of allergy as well as population-based investigation of molecular IgE-recognition profiles. Keynote Speakers are Rudolf Valenta (Austria), Marianne van Hage (Sweden), Hans Grönlund (Sweden), Stephen Durham (UK), Sebastian Johnston (UK), Marek Jutel (Poland), Alexander Gabibov (Russia), Natalia Nenasheva, Musa Khaitov (Russia), Winfried Pickl (Austria), Hannes Stockinger (Austria). Registration Registration is free of charge. To participate in the conference, you... https://www.meduniwien.ac.at/web/en/about-us/events/detail/mmam-2018-moscow-mollecular-allergology-meeting/?L=3
Analysis of natural immunity following coronavirus infection ... protective immunity following an infection. It is hoped that the results of the study will provide a solid basis for developing a vaccine," says Rudolf Valenta from MedUni Vienna's Center for Pathophysiology, Infectiology and Immunology, "we have to accept that the virus is now among us, just like influenza... https://www.meduniwien.ac.at/web/en/about-us/news/detailsite/2020/news-im-april-2020/analysis-of-natural-immunity-following-coronavirus-infection/medicine-science/?L=3
Analysis of natural immunity following coronavirus infection ... protective immunity following an infection. It is hoped that the results of the study will provide a solid basis for developing a vaccine," says Rudolf Valenta from MedUni Vienna's Center for Pathophysiology, Infectiology and Immunology, "we have to accept that the virus is now among us, just like influenza... https://www.meduniwien.ac.at/web/en/about-us/news/detailsite/2020/news-im-april-2020/analysis-of-natural-immunity-following-coronavirus-infection/?cHash=39bc95a4654beacdb7e4725581645b78&tx_news_pi1%5BoverwriteDemand%5D%5Bcategories%5D=2
Analysis of natural immunity following coronavirus infection ... protective immunity following an infection. It is hoped that the results of the study will provide a solid basis for developing a vaccine," says Rudolf Valenta from MedUni Vienna's Center for Pathophysiology, Infectiology and Immunology, "we have to accept that the virus is now among us, just like influenza... https://www.meduniwien.ac.at/web/en/about-us/news/detailsite/2020/news-im-april-2020/analysis-of-natural-immunity-following-coronavirus-infection/?L=3
Weltweit erster wirksamer Impfstoff gegen Gräserpollen-Allergie entwickelt ... notwendig macht und auch geringere Nebenwirkungen hat. Diese Technologie wurde am Christian Doppler Labor für Allergieforschung unter der Leitung von Rudolf Valenta an der MedUni Wien in Kooperation mit dem Wiener Unternehmenspartner Biomay AG (Leitung: CEO Rainer Henning) entwickelt. Das Unternehmen ist... https://www.meduniwien.ac.at/web/ueber-uns/news/detailseite/2018/news-jaenner-2018/weltweit-erster-wirksamer-impfstoff-gegen-graeserpollen-allergie-entwickelt/?tx_news_pi1%5BoverwriteDemand%5D%5Bcategories%5D=2&cHash=9a2492623406782ee3a542f982a933eb
Weltweit erster wirksamer Impfstoff gegen Gräserpollen-Allergie entwickelt ... notwendig macht und auch geringere Nebenwirkungen hat. Diese Technologie wurde am Christian Doppler Labor für Allergieforschung unter der Leitung von Rudolf Valenta an der MedUni Wien in Kooperation mit dem Wiener Unternehmenspartner Biomay AG (Leitung: CEO Rainer Henning) entwickelt. Das Unternehmen ist... https://www.meduniwien.ac.at/web/ueber-uns/news/detailseite/2018/news-jaenner-2018/weltweit-erster-wirksamer-impfstoff-gegen-graeserpollen-allergie-entwickelt/?cHash=9a2492623406782ee3a542f982a933eb&tx_news_pi1%5BoverwriteDemand%5D%5Bcategories%5D=2
First vaccine in the world developed against grass pollen allergy ... Christian Doppler Laboratory for Allergy Research at MedUni Vienna, under the direction of Rudolf Valenta, in collaboration with Viennese partner company Biomay AG (CEO: Rainer Henning). This company specialises in discovering and developing innovative allergy therapeutics. Revolutionary Viennese product... https://www.meduniwien.ac.at/web/en/about-us/news/detailsite/2018/news-jaenner-2018/first-vaccine-in-the-world-developed-against-grass-pollen-allergy/?tx_news_pi1%5BoverwriteDemand%5D%5Bcategories%5D=11&cHash=fb2b9e60e1cd9bb05003baab924cd8e7
First vaccine in the world developed against grass pollen allergy ... Christian Doppler Laboratory for Allergy Research at MedUni Vienna, under the direction of Rudolf Valenta, in collaboration with Viennese partner company Biomay AG (CEO: Rainer Henning). This company specialises in discovering and developing innovative allergy therapeutics. Revolutionary Viennese product... https://www.meduniwien.ac.at/web/en/about-us/news/detailsite/2018/news-jaenner-2018/first-vaccine-in-the-world-developed-against-grass-pollen-allergy/?cHash=fb2b9e60e1cd9bb05003baab924cd8e7&tx_news_pi1%5BoverwriteDemand%5D%5Bcategories%5D=11
Weltweit erster wirksamer Impfstoff gegen Gräserpollen-Allergie entwickelt ... notwendig macht und auch geringere Nebenwirkungen hat. Diese Technologie wurde am Christian Doppler Labor für Allergieforschung unter der Leitung von Rudolf Valenta an der MedUni Wien in Kooperation mit dem Wiener Unternehmenspartner Biomay AG (Leitung: CEO Rainer Henning) entwickelt. Das Unternehmen ist... https://www.meduniwien.ac.at/web/ueber-uns/news/detailseite/2018/news-jaenner-2018/weltweit-erster-wirksamer-impfstoff-gegen-graeserpollen-allergie-entwickelt/?tx_news_pi1%5BoverwriteDemand%5D%5Bcategories%5D=11&cHash=fb2b9e60e1cd9bb05003baab924cd8e7
First vaccine in the world developed against grass pollen allergy ... Christian Doppler Laboratory for Allergy Research at MedUni Vienna, under the direction of Rudolf Valenta, in collaboration with Viennese partner company Biomay AG (CEO: Rainer Henning). This company specialises in discovering and developing innovative allergy therapeutics. Revolutionary Viennese product... https://www.meduniwien.ac.at/web/en/about-us/news/detailsite/2018/news-jaenner-2018/first-vaccine-in-the-world-developed-against-grass-pollen-allergy/?cHash=9a2492623406782ee3a542f982a933eb&tx_news_pi1%5BoverwriteDemand%5D%5Bcategories%5D=2